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Abstract. Innovations and new health technology can significantly im-
prove the clinical practice, health outcomes, and life expectancy. How-
ever, governments must make a decision about which intervention is of 
the best value, offers the best improvement in terms of health gain, 
fewer adverse events, and all of that in the frame of the restricted re-
sources. Exploring the literature we can see that by using decision-
making science and Health technology assessment (HTA) a lot of coun-
tries had achieved the balance in the innovative health care world. 
Their approaches, framework, and development give us an insight of 
limitations and strengths that decision-makers and HTA agencies face to 
assess and optimize outcomes and the benefit-harm balance of new 
medicines and diagnostic tools. Bringing HTA in countries in develop-
ment is also a concern that has economic and political restrictions and it 
raises a lot of questions and challenges for development of decision 
making sciences itself. Our findings suggest that within all the limita-
tions and future challenges that are to come and even we do not have 
the perfect information, decision must be made. In most health care 
situations clinical and economic evidence must be extrapolated through 
time or space, transferred from one study to another, or combined and 
linked in a way that they can demonstrate a balance between the costs 
and consequences and capture the benefits of new technologies, over-
come uncertainties, and recognize the value of innovation, all within 
the limits of overall health resources and constrained health budgets of 
the respective country. 
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Introduction. Throughout the twentieth century health systems have 
developed at different speeds, and with different degrees of complexity, 
reflecting the diverse political and social conditions in each country. As a 
result, na-tional health care systems have become more advanced, intro-
ducing a range of technological innovations such as new medicines and 
diagnostic tools, telemedicine, and surgical equipment that have brought 
remarkable improvements in terms of health gains, better quality of life, 
and fewer adverse events. Adopting innovations in clinical practice pro-
vides a major opportunity for health professionals to improve the effec-
tiveness, safety, and quality of treatment. Although many innovations 
have the potential to bring a range of benefits to patients and the health 
care system, their spread can cause problems when there are constraints 
on resources as some innovations bring the same or improved effective-
ness and quality of care at significantly lower costs, while other innova-
tions increase overall health expenditures. Even though innovations can 
significantly improve clinical practice, the rapid growth of medical tech-
nology and the increasing volume of new knowledge have made it virtu-
ally impossible for providers to keep pace with new treatments. As a 
result, inappropriate practices and variations in how technologies are 
used have become part of health care provision across the world, indi-
cating that the most effective and efficient technologies are not always 
being used. Physicians often hesitate to change long standing practices, 
which may stop the uptake of new and more effective interventions [1]. 
Many countries face the challenge of utilizing the benefits of innovation 
while managing health care budgets and following the basic principles of 
equity, access, and choice. Considering the rapid growth in health tech-
nologies, and other changes in health care, governments must manage 
their limited resources by making a decision which interventions are of 
the best value and how they should be used. So, decision making already 
became essential part of health care systems [1,2]. Decision making in-
volves choosing an action after weighting the risk, benefits, and costs of 
the options available to the individual patient or the patient population 
[1,3]. Decision-analytic models have been improved to be essential for 
informing treatment decisions and designing clinical practice guidelines 
to optimize outcomes and the benefit-harm balance for each individual 
patient [2,4]. This research review contribution explores and evaluates 
literature generally and discusses the role of decision making sciences on 
innovation, the integrity, and growth of health care in general. Further-
more, this descriptive framework and overview is sought to be very im-
portant in identifying research gaps and recommending new research 
areas in countries with lower economic growth that experience the high-
est pressure on public budgets.  
 
Discussion. Achieving the balance in health care. Adopting new health 
technologies has a huge impact on the limited national budgets resulting 
in tensions between delivering cost effective health care and improving 
or sustaining a country’s manufacturing and research base. It is therefore 
increasingly important to have a balance between affordable health care 
and innovative health technologies. To meet this end, it is necessary to 
consider the value of a product both in medical and economic terms and 
also to consider who benefits from innovations, its optimal usage, and 
the appropriate placement in health care [1,2,3,5]. Moving further, to 
conduct all this diversity of data and to provide a unique input into the 
decision making process of the health systems, a lot of countries had 
developed multidisciplinary field of policy analysis agencies known as 
Health technology assessment (HTA) agencies [6]. As defined in Interna-
tional Society for Pharmacoeconomics and Outcomes Research’s (ISPOR), 
HTA is “a form of policy research that examines short and long term con-
sequences of the application of a healthcare technology. Properties as-
sessed include evidence of safety, efficacy, patient-reported outcomes, 
real world effectiveness, cost and cost-effectiveness as well as social, 
legal, ethical, and political impacts” [7]. HTA has shown its improving role 
in growing the national priority-setting and health policy processes [6]. A 
lot of countries had developed systems to evaluate innovations. In the 
United Kingdom, for example, the National Institute for Health and Clini-
cal Excellence (NICE) was one of the first review bodies to provide faster 
access to modern treatments through a systematic review process and 
evidence-based decision-making [8]. HTA contributes in many ways to 
the knowledge base for improving the quality of care, in supporting the 
development and updating of clinical practice guidelines and health ser-
vice standards [9]. Without good evidence, the spread of technologies is 
more likely to be influenced by social, financial, profession-al, and institu-
tional factors, and may not produce the best outcomes or the most effi-
cient use of resources [1,2]. However, Kristensen et al. (2009) in their 
reports for the EUnetHTA work have suggested that despite its policy 
goals, HTA must always be firmly rooted in research and the scientific 
methods [10]. Considering the increased uses of pharmaceuticals and 
other technologies, decision-makers have been encouraged to rely on 
HTA while determining the reimbursement status and pricing of interven-
tions and pharmaceuticals. HTA with their evidence can reduce or elimi-
nate interventions that are unsafe and ineffec-tive, or whose cost is too 
high compared to the benefits. As an example, McNeil et al. (2001) re-
ported the use of HTA in identifying technologies that are underused (eg, 
preventive screening, smoking, cessation interventions) and identifies the 
reasons for that [11]. Battista and Hodge (1999) called HTA also ‘the 
bridge between evidence and policy making’, because it provides infor-
mation for health care decision-makers at macro-, meso-, and micro-
levels [12]. Parts and approaches of HTA . HTA involves different parts 
and broad range of approaches. Part of HTA report can be clinical effec-
tiveness evaluations as well as economic evaluations, while approaches 
could be divided in qualitative (narrative review and evidence tables) and 
quantitative (meta analysis and decision analysis). Adequately, HTA re-
ports go beyond qualitatively reviewing and summarizing the evidence of 
published international studies and nowadays use decision-analytic 
methods also to ensure that the results reflect the context of the investi-
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gated country’s health care system [1,2,3]. According its broad concept of 
technology, the principles and purview of HTA include medical interven-
tions it self, as well as organizational interventions, and even of health 
care reform, since all of them could be considered as interventions in the 
health system. HTA can offer to decision-makers the broad picture of 
assessment of the potential effects on health, the consequences for the 
health system, the society in which a technology is to be introduced or 
excluded, and the different options from performing a health care reform 
[3,13]. In reviewing systematically the evidence on a health technology, 
HTA uses a multidisciplinary framework to ask four main questions (UK 
National Health Service R&D Health Technology Assessment Program 
2003) as: “Is the technology effective? For whom does the technology 
work? What costs are entailed in its use? How does the technology com-
pare with available treatment alternatives?” [14]. Framework and Devel-
opment of HTA. In Europe, the first organizations dedicated in evaluat-
ing health care technologies were set up in the 1980s, initially at the 
regional and local level in France and Spain and, later, on the regional 
level in Sweden in 1987 [15,16]. Further on, over the following next 10 
years most countries set up HTA programs, either by providing new agen-
cies or institutes, or by setting up academic units or governmental and 
non-governmental entities. These groups were generally independent 
review bodies that produced and disseminated assessment reports on a 
range of topics, and entities under governmental mandate (as from 
health ministries) responsible for making decisions and setting priorities 
on issues such as the reimbursement and pricing of health technologies. 
Kristensen et al. (2005), in the report for EUnetHTA discusses how over 
the following period with additional investment comes a growing scien-
tific recognition that HTA must be consistent across applications, trans-
parent, and practical. More countries are placing greater emphasis on 
ensuring that the results of HTA are considered in key decision-making 
processes [17]. Nowadays, even many European agencies share the same 
objectives their structures have developed and currently vary in responsi-
bility and membership of HTA bodies. There are also differences in terms 
of how HTA organizations set priorities, the degree to which stakeholders 
are permitted to provide input, how results are communicated, how HTA 
organizations interact with national reimbursement authorities, and how 
explicitly entities use decision analytic models and cost effectiveness 
analysis. Summary of studies published by the International Society of 
Pharmacoeconomic and Outcome Research report the diversity and les-
sons learned from different countries and perspectives about HTA 
[18,19,20]. In many countries, the health ministry or independent institu-
tions are often involved in managing various aspects of the assessment. 
On the other hand, in many social insurance funded health systems the 
assessment is done mainly by insurance organizations, as Hutton et al. 
(2006) reported [21]. However, even in these countries, there is some 
degree of overseeing by the Ministry of Health, and often the Ministry of 
Social Affairs or Security. Countries also differ in terms of how the reim-
bursement and pricing process are linked. Reimbursement decisions are 
sometimes made before pricing, while in other cases both the reimburse-
ment and price are considered at the same time before a final decision is 
determined (in Sweden, the Netherlands, and Finland). An important role 
in the assessment have conditional approvals, because they allow use of 
the technology under limited conditions in an attempt to minimize uncer-
tainty until the further data are collected and the subsequent re-
evaluation of the product is done [22]. Considering the severe diseases 
and orphan drugs, even they have poor cost effectiveness ratio usually 
they are covered. Overall, health assessment evidence seems to have the 
biggest impact on decisions about drugs with broad use and therefore 
significant potential budget impact [1,2]. One of the main results of the 
assessments is also helping in the development of clinical or practice 
guidelines. Guidelines usually include recommendations on priority-
setting, and provide national support to help decision-makers. However, 
health economic data and evidence are not used as well as they could be 
when developing guidelines, with only a few recommendations grounded 
in HTA. Berg et al. (2004) suggests that this could be caused by a gap 
between the data generated and the requirements of clinical practice, 
aversion among the doctors to combine economics and health, and the 
fact that guidelines rely more on data on effectiveness, rather than on 
cost effectiveness. It was argued that for influencing the use or uptake of 
new health technology guidelines are of limited value [23]. Cox et al. 
(2007) reported that this situation was probably made worse by the lack 
of coordination between the bodies that produce guidelines and those 
that set priorities and fund HTA studies [18]. Lessons learned. When the 
United Kingdom introduced the National Institute for Clinical Excellence 
(NICE), which subsequently became the National Institute for Health and 
Clinical Excellence (that provides guidance on new technologies and 
treatment of diseases), it significantly contributed to the globalization of 
HTA [8,19]. NICE aims to establish a transparent review process to deter-
mine how well the treatment work clinically in relation to how much it 
will cost, considering both clinical and cost-effectiveness ratios in devel-
oping its guidance [8,19,24]. The appraisals are conducted by an inde-
pendent Technology Appraisal Committee with membership from key 
stakeholders: National Health Service, patient advocacy groups, academ-
ia, and the medical technology industries [8,19]. However, Drummond et 
al. (2009) discusses the debate for main achievements of NICE and many 
major unresolved issues of NICE and the UK perspective health care sys-
tem. Even though in the UK the approach followed by NICE has proved 
workable, many important issues remain unresolved and future chal-
lenge for HTA development in general [24]. Despite the note that tech-
nology assessment had a beginning in the United States public sector, 
HTA processes appear to be more advanced outside of the U.S. [19]. U.S. 
has some unique challenges for HTA organizations because of the decen-
tralized and privately based health care system and different cultural atti-
tudes toward the appropriate role of government. And as Gordon et al. 
(2003) and Boyles et al. (1996) have argued, the U.S. even nowdays re-
mains to be characterized by “deliberatively obstruction-oriented politi-
cal structure” that frustrates government programs, even if they reflect 
popular aspirations and values [25,26]. Advancing HTA in this climate 
remains future challenge for U.S. The climate of health technology as-
sessment in Germany had its reform in health care when during 2004 one 
of the newest HTA models was introduced as an independent body 
named the Institute for Quality and Efficiency in Health Care (Institut für 
Qualität und Wirtschaftlichkeit im Gesundheitswesen [IQWiG]) [27], that 
is similar to NICE and conducts and assesses studies of pharmaceuticals, 
surgical procedures, clinical practice guidelines, and disease management 
programs. These evaluations are usually commissioned by Germany’s 
Federal Joint Commission, Gemeinsamer Bundesausschuss (G-BA), or the 
Federal Ministry of Health. Most products are automatically reimbursed 
once approved with a reference price system and unless a medicine can 
demonstrate clear innovation or therapeutic superiority over existing 
therapies, reference pricing is applied by the G-BA [19,28]. Fricke et al. 
(2009) reported the use of HTA and its impact on the healthcare budget 
in Germany and discussed future issues assessing health technology, 
among which were data related to the value of resource items, the rele-
vance of thresholds, uncertainty, the transferability of economic infor-
mation, the relevance of the real-world data, effects of HTA on budgets, 
reimbursement and other structural issues [28]. Challenges and Oppor-
tunities of the future. Moving further, Neumann et al. (2009) discussed 
very clearly that there should be no surprise of the diversity of HTA activi-
ties because it reflects the different health care and political systems, 
with different mandates, funding mechanisms, and roles in policy formu-
lation [20]. However, one of the main aims of every country remains to 
be the huge need in developing rigorous scientific evidence evaluations, 
as well as procedures that are transparent, fair, predictable, and efficient. 
And there remains considerable room of challenge in moving HTA to-
wards more predictable and rational evidence. O'Donnell et al. (2009) 
and Drummond et al. (2009) discuss the need that HTA recommenda-
tions must be reviewed constantly when considering the changes of cost-
effectiveness of a technology and patient demand for that technology 
over time. They suggest that this will demand for greater collaboration 
among stakeholders, particularly HTA staff, government officials, industry 
representatives, health providers and patients, starting from the ade-
quate level of understanding of the HTA process. In the interest for HTA 
to be of optimal benefit, the assessment process needs to be linked with 
innovation and other aspects of policy-making, and it must recognize the 
complexities of decision-making, where subjective and normative con-
cerns are considered. Otherwise, HTA could be limited in its power to 
impact on the policy process and subsequent access to new and effective 
products [18,24]. Although the difficulty HTA has faced in the past and 
there will be a lot of them in the future, it is likely that the impact on the 
innovation exists and that strengths the future work that it should be 
more based on research on the structure, process, and outcome of HTA 
systems [18,24]. The European Network of HTA offers a better coopera-
tion among assessment groups and can help in developing those new 
methodologies, enhance the transferability and transparency of HTA 
recommendations, and potentially improve the efficiency and accounta-
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bility of the HTA process [29]. This is a European level project established 
to create an effective and sustainable network for HTA across Europe 
that could bring all the experiences, data, evidences, strengths and limi-
tations of European countries in a collaborative work in supporting and 
improving national HTA processes. As defined by EUnetHTA its objective 
is “to increase the impact of HTA, strengthen the link between HTA and 
healthcare policy making in the EU and its Member States, and support 
countries with limited experience in HTA“ [10,29]. Kristensen et al. (2009) 
discussed and reported in details structures, methodologies, and tools 
developed by EUnetHTA. They report also that based on the results of 
the working process during the project itself EUnetHTA can already be 
considered as a concrete achievement of transnational decision making 
and HTA work in Europe. This structure is planned to build a solid founda-
tion for concrete European collaboration in HTA [17,29]. And as a project 
in progress is the EUnetHTA Joint Action 2 (2012-2015) with its aim “to 
strengthen the practical application of tools and approaches to cross-
border HTA collaboration” [30]. Bringing HTA in countries in development 
is also a concern that has a huge number of limitations (political, eco-
nomic and social) and it raises a lot of questions and challenges for devel-
opment of HTA itself. Beside that, remains the fundamental idea of HTA 
to guide the healthcare systems in spending their limited budgets in max-
imizing value of health, and this remains the future challenge for those 
countries. And of course, this requires resources as well as leadership, 
not only among government officials, but among individuals in profes-
sional organizations, including the academics and research centers. Ethi-
cal aspects of HTA. The most important parts of ethics in HTA are the ac-
tual consequences of applying the chosen technology. The HTA analyses 
itself is an ethical question even from the moment when we start the 
point of choice in the area we want to focus our decision [31]. INAHTA’S 
reports that handle ethical issues discusses the different understandings 
of the consequences of HTA, as it could refer to the value of the HTA 
results from the ethical perspective, i.e. the relevance of HTA assess-
ments for making and justifying decisions; also it could be the actual 
ethical implications of an HTA appraisal, assuming the recommendations 
that the HTA reports [32]. As defined by Duthie et al (2011), “ethical 
analysis requires systematic reflection and reasoning about what is of 
fundamental importance to those developing, using, and affected by a 
particular technology and moves systematically to some course of action 
that best reflects this importance” [31]. The aim of ethics in HTA is to 
HTA by making it more comprehensive, transparent, transferable, and 
more useful to HTA users. In its report, Duthie et al. (2011) highlighted 
the weaknesses of those issues that exist in the current literature and 
they offered three steps forward to help improve them: “acknowledge 
and use relevant expertise, further develop models for conducting and 
reporting ethics analyses, and make use of untapped resources in the 
literature“ [31]. On the other hand, the INAHTA’S final reports give us an 
insight of the questions that arise in different aspects of ethical analyses 
of HTA evaluations, it discusses every question separately and gives rec-
ommendations of steps that could every HTA agency undertake in order 
to develop and share improved skills related to an ethical analyses [32].  
 
Conclusions. The application of this framework within the landscape of 
health care innovations can inform the development of decision making 
sciences in societies confronting the challenges of supporting economic 
growth and providing basic health care. Within all the limitations and 
future challenges that are to come and even we do not have the perfect 
information, decision must be made. In most health care situations clini-
cal and economic evidence must be extrapolated through time or space, 
transferred from one study population to another, or combined and 
linked in a way that they can demonstrate a balance between the costs 
and consequences. The findings of our review suggest that decision mak-
ing and HTA can play a valuable role in health care and it has improved to 
be a focal point of an ongoing struggle across a range of countries. How-
ever, the process must include transparency, relevance, depth, and usa-
bility. Assessments need to use robust methods and be supplemented by 
other important criteria in the decision-making process. By maximizing 
the potential of HTA in health care system, decision-makers will be able 
to implement decisions that capture the benefits of new technologies, 
overcome uncertainties, and recognize the value of innovation, all within 
the limits of overall health resources and constrained budgets. This arti-
cle is not attempt to resolve different issues, rather than its aim is getting 
familiar, articulating, comparing, and contrasting different experiences in 
health care systems and processes. This template can be seen as useful 
for purposes when implementing a research, changing a health system, 
building an HTA agency, and across the areas of science, policy, and pop-
ulation in the countries in development that aim to get familiar with 
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